MindMed Bolsters Management Team, Appoints Peter Mack PhD as Vice President of Pharmaceutical Development

MindMed (NASDAQ: MNMD) (NEO: MMED), a leading psychedelic-inspired medicine company has appointed Peter Mack PhD as Vice President of Pharmaceutical Development.

As MindMed progresses it’s Discover and Develop efforts for multiple commercial clinical programs including LSD and an ibogaine derivative, 18-MC, Peter will lead MindMed’s product development activities across its entire portfolio of investigational drugs. In addition, Peter will oversee partnerships with Contract Manufacturing Development Organizations and other discovery efforts to support the advancement of MindMed’s proprietary new chemical entities.

Peter joins MindMed from AstraZeneca, where he was the Director of Manufacturing for Inhalation Product Development. Peter previously worked at Pearl Therapeutics (acquired by AstraZeneca in 2013) where he helped pioneer the pharmaceutical development of inhaled combination therapies for highly prevalent respiratory diseases.

Peter holds a dual PhD in Medical Engineering / Medical Physics from Harvard Medical School and Massachusetts Institute of Technology (MIT), where he was a National Institute of Health (NIH) Biomechanics Training Grant Recipient.  Peter also holds a Masters of Science in Mechanical Engineering from MIT.  During his time in academia and the pharmaceutical industry, Peter contributed to numerous peer reviewed articles and patents. 

MindMed is constantly on the hunt to find the best people to help us shape the future of psychedelic medicine from discovery to delivery. We are excited to have Peter join us on our mission and help us craft a world class pharmaceutical development organization.

J.R. Rahn, Chief Executive Officer and Co-founder of MindMed

To view the original press release in its entirety click here